Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II

Molecular Endocrinology

Volumn 20, Issue 5, 2006, Pages 953-970

  Hunyady, László ^a   Catt, Kevin J ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II;

ANIMAL; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION;

EID: 29344452247     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0536     Document Type: Short Survey

References (205)

1. Tigerstedt R, Bergman PG 1898 Niere and Kresilauf. Scand Arch Physiol 8:223-271
2. Braun-Menendez E, Fasciolo JC, Leloir LF, Muńoz JM 1940 The substance causing renal hypertension. J Physiol (Lond) 98:283-298
3. Page IH, Helmer OM 1940 A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med 71:29-42
4. Glossmann H, Baukal A, Catt KJ 1974 Angiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides. J Biol Chem 249:664-666
5. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T 2000 International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472
6. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE 1991 Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233-236
7. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T 1991 Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351:230-233
8. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T 1993 Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268:24543-24546
9. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ 1993 Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268:24539-24542
10. 2 receptor. Trends Endocrinol Metab 11:1-6
11. Sequeira Lopez ML, Gomez RA 2004 The role of angiotensin II in kidney embryogenesis and kidney abnormalities. Curr Opin Nephrol Hypertens 13:117-122
12. Crowley SD, Tharaux PL, Audoly LP, Coffman TM 2004 Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand 181:561-570
13. Lavoie JL, Sigmund CD 2003 Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 144:2179-2183
14. Ferrario C, Abdelhamed AI, Moore M 2004 AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Curr Med Res Opin 20:279-293
15. Re RN 2003 Intracellular renin and the nature of intracrine enzymes. Hypertension 42:117-122
16. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R 2004 Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 120:5-13
17. Danser AH 2003 Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 35:759-768
18. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I 2004 Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6:499-506
19. Hunyady L, Turu G 2004 The role of the AT(1) angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 15:405-408
20. Carey RM, Siragy HM 2003 Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24:261-271
21. Thomas WG, Mendelsohn FA 2003 Angiotensin receptors: form and function and distribution. Int J Biochem Cell Biol 35:774-779
22. Ferrario CM, Chappell MC 2004 Novel angiotensin peptides. Cell Mol Life Sci 61:2720-2727
23. Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM, Psaty BM, Klungel OH 2004 Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 64:1801-1816
24. Schurmann M, Reichel P, Muller-Myhsok B, Dieringer T, Wurm K, Schlaak M, Muller-Quernheim J, Schwinger E 2001 Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med 249:77-83
25. Fei DT, Coghlan JP, Fernley RT, Scoggins BA, Tregear GW 1980 Peripheral production of angiotensin II and III in sheep. Circ Res 46:I135-I137
26. Spät A, Hunyady L 2004 Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 84:489-539
27. Sernia C 2001 A critical appraisal of the intrinsic pancreatic angiotensin-generating system. JOP 2:50-55
28. Nielsen AH, Schauser KH, Poulsen K 2000 Current topic: the uteroplacental renin-angiotensin system. Placenta 21:468-477
29. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY 2001 Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276:48623-48626
30. Chai SY, Fernando R, Peck G, Ye SY, Mendelsohn FA, Jenkins TA, Albiston AL 2004 The angiotensin IV/AT4 receptor. Cell Mol Life Sci 61:2728-2737
31. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T 2003 Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100:8258-8263
32. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G 2000 Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153
33. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H 2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
34. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I 1979 Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 90:19-23
35. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M 2001 The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88:1L-20L
36. Keys JR, Greene EA, Koch WJ, Eckhart AD 2002 Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 40:660-666
37. Hescheler J, Rosenthal W, Hinsch K-D, Wulfern M, Trautwein W, Schultz G 1988 Angiotensin II-induced stimulation of voltage-dependent Ca2+ currents in an adrenal cortical cell line. EMBO J 7:619-624
38. i. Am J Physiol Cell Physiol 271:C1340-C1349
39. Maturana AD, Casal AJ, Demaurex N, Vallotton MB, Capponi AM, Rossier MF 1999 Angiotensin II negatively modulates L-type calcium channels through a pertussis toxin-sensitive G protein in adrenal glomerulosa cells. J Biol Chem 274:19943-19948
40. Ushio-Fukai M, Griendling KK, Akers M, Lyons PR, Alexander RW 1998 Temporal dispersion of activation of phospholipase C-β1 and -γ isoforms by angiotensin II in vascular smooth muscle cells. Role of αq/11, α12, and β γ G protein subunits. J Biol Chem 273:19772-19777
41. 2+ channels in rat portal vein myocytes. J Biol Chem 272:23180-23185
42. Ushio-Fukai M, Alexander RW, Akers M, Lyons PR, Lassegue B, Griendling KK 1999 Angiotensin II receptor coupling to phospholipase D is mediated by the βγ subunits of heterotrimeric G proteins in vascular smooth muscle cells. Mol Pharmacol 55:142-149
43. Rattan S, Puri RN, Fan YP 2003 Involvement of rho and rho-associated kinase in sphincteric smooth muscle contraction by angiotensin II. Exp Biol Med (Maywood) 228:972-981
44. Baukal AJ, Hunyady L, Catt KJ, Balla T 1994 Evidence for participation of calcineurin in potentiation of agonist-stimulated cyclic AMP formation by the calcium-mobilizing hormone, angiotensin II. J Biol Chem 269:24546-24549
45. Saito Y, Berk BC 2002 Angiotensin II-mediated signal transduction pathways. Curr Hypertens Rep 4:167-171
46. Yin G, Yan C, Berk BC 2003 Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 35:780-783
47. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R 1997 Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ. Science 275:394-397
48. Luchtefeld M, Drexler H, Schieffer B 2001 Role of G β-subunit in angiotensin II-type 1 receptor signaling. Biochem Biophys Res Commun 280:756-760
49. 1 receptor. J Biol Chem 272:23382-23388
50. Kyaw M, Yoshizumi M, Tsuchiya K, Kagami S, Izawa Y, Fujita Y, Ali N, Kanematsu Y, Toida K, Ishimura K, Tamaki T 2004 Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 65:832-841
51. Haendeler J, Yin G, Hojo Y, Saito Y, Melaragno M, Yan C, Sharma VK, Heller M, Aebersold R, Berk BC 2003 GIT1 mediates Src-dependent activation of phospholipase Cγ by angiotensin II and epidermal growth factor. J Biol Chem 278:49936-49944
52. Yin G, Haendeler J, Yan C, Berk BC 2004 GIT1 functions as a scaffold for MEK1-extracellular signal-regulated kinase 1 and 2 activation by angiotensin II and epidermal growth factor. Mol Cell Biol 24:875-885
53. Yin G, Zheng Q, Yan C, Berk BC 2005 GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J Biol Chem 280:27705-27712
54. Schiffrin EL, Touyz RM 2004 From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287:H435-H446
55. Wang Z, Rao PJ, Shillcutt SD, Newman WH 2005 Angiotensin II induces proliferation of human cerebral artery smooth muscle cells through a basic fibroblast growth factor (bFGF) dependent mechanism. Neurosci Lett 373:38-41
56. Zhang A, Ding G, Huang S, Wu Y, Pan X, Guan X, Chen R, Yang T 2005 c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells. Am J Physiol Renal Physiol 288:F1118-F1124
57. Chiu T, Santiskulvong C, Rozengurt E 2005 EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 288:G182-G194
58. Foster RH 2004 Reciprocal influences between the signalling pathways regulating proliferation and steroidogenesis in adrenal glomerulosa cells. J Mol Endocrinol 32:893-902
59. Otis M, Campbell S, Payet MD, Gallo-Payet N 2005 Angiotensin II stimulates protein synthesis and inhibits proliferation in primary cultures of rat adrenal glomerulosa cells. Endocrinology 146:633-642
60. Rossi F, Ferraresi A, Romagni P, Silvestroni L, Santiemma V 2002 Angiotensin II stimulates contraction and growth of testicular peritubular myoid cells in vitro. Endocrinology 143:3096-3104
61. Takeda H, Katagata Y, Hozumi Y, Kondo S 2004 Effects of angiotensin II receptor signaling during skin wound healing. Am J Pathol 165:1653-1662
62. Melaragno MG, Wuthrich DA, Poppa V, Gill D, Lindner V, Berk BC, Corson MA 1998 Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res 83:697-704
63. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC 2000 Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor β receptor. Key role for the p66 adaptor protein Shc. J Biol Chem 275:15926-15932
64. Du J, Sperling LS, Marrero MB, Phillips L, Delafontaine P 1996 G-protein and tyrosine kinase receptor cross-talk in rat aortic smooth muscle cells: thrombin- and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 218:934-939
65. Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, Catt KJ 2004 Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol Endocrinol 18:2035-2048
66. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T 2001 Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease- dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276:7957-7962
67. Frank GD, Eguchi S 2003 Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal 5:771-780
68. Shah BH, Catt KJ 2003 A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol Sci 24:239-244
69. Garcia-Sainz JA, Garcia-Caballero A, Gonzalez-Espinosa C 1998 Angiotensin AT1 receptors in clone 9 rat liver cells: Ca2+ signaling and c-fos expression. Eur J Pharmacol 362:235-243
70. Shah BH, Catt KJ 2002 Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase Cδ, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. Mol Pharmacol 61:343-351
71. Olivares-Reyes JA, Shah BH, Hernandez-Aranda J, Garcia-Caballero A, Farshori MP, Garcia-Sainz JA, Catt KJ 2005 Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Mol Pharmacol 68:356-364
72. Touyz RM, Schiffrin EL 2000 Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52:639-672
73. Claing A, Laporte SA, Caron MG, Lefkowitz RJ 2002 Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and ss-arrestin proteins. Prog Neurobiol 66:61-79
74. Luttrell LM, Lefkowitz RJ 2002 The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465
75. Gaborik Z, Hunyady L 2004 Intracellular trafficking of hormone receptors. Trends Endocrinol Metab 15:286-293
76. Prossnitz ER 2004 Novel roles for arrestins in the postendocytic trafficking of G protein-coupled receptors. Life Sci 75:893-899
77. Thomas WG, Qian H 2003 Arresting angiotensin type 1 receptors. Trends Endocrinol Metab 14:130-136
78. 1 angiotensin receptor. J Biol Chem 269:31378-31382
79. 1a receptor is localized to a serine/threonine-rich region of its cytoplasmic tail. Mol Pharmacol 54:935-941
80. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS 2000 Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275:17201-17210
81. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG 2001 Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis. J Biol Chem 276:19452-19460
82. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ 2003 Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787
83. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW 2000 β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148:1267-1281
84. Ge L, Ly Y, Hollenberg M, Defea K 2003 A β-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. J Biol Chem 278:34418-34426
85. Ge L, Shenoy SK, Lefkowitz RJ, Defea K 2004 Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both β-arrestin-1 and -2. J Biol Chem 279:55419-55424
86. Hunton DL, Barnes WG, Kim J, Ren XR, Violin JD, Reiter E, Milligan G, Patel DD, Lefkowitz RJ 2005 β-Arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol 67:1229-1236
87. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J 2002 AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 277:9268-9277
88. Miura S, Zhang J, Matsuo Y, Saku K, Karnik SS 2004 Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens Res 27:765-770
89. Luttrell LM, Ferguson SSG, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ 1999 β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes. Science 283:655-661
90. 1 angiotensin receptor. Proc Natl Acad Sci USA 93:10040-10045
91. Haendeler J, Ishida M, Hunyady L, Berk BC 2000 The third cytoplasmic loop of the angiotensin II type 1 receptor exerts differential effects on extracellular signal-regulated kinase (ERK1/ERK2) and apoptosis via Ras- and Rap1-dependent pathways. Circ Res 86:729-736
92. Booz GW, Day JN, Baker KM 2002 Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443-1453
93. Phillips MI, Kagiyama S 2002 Angiotensin II as a proinflammatory mediator. Curr Opin Investig Drugs 3:569-577
94. Chen X, Wang J, Zhou F, Wang X, Feng Z 2003 STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells. Kidney Int 64:459-467
95. Mascareno E, Siddiqui MA 2000 The role of Jak/STAT signaling in heart tissue renin-angiotensin system. Mol Cell Biochem 212:171-175
96. Wang TL, Yang YH, Chang H, Hung CR 2004 Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol 37:785-794
97. Ihle JN 1996 STATs: signal transducers and activators of transcription. Cell 84:331-334
98. 1A receptor activates transcription factor-Stat91 and/or a related protein. J Biol Chem 269:31443-31449
99. 1 receptor. Nature 375:247-250
100. 1 receptor. J Biol Chem 273:7703-7708
101. Seta K, Sadoshima J 2003 Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor. J Biol Chem 278:9019-9026
102. Inada Y, Nakane T, Chiba S 2003 Relationship between ligand binding and YIPP motif in the C-terminal region of human AT1 receptor. Biochim Biophys Acta 1640:33-41
103. Frank GD, Saito S, Motley ED, Sasaki T, Ohba M, Kuroki T, Inagami T, Eguchi S 2002 Requirement of Ca(2+) and PKCdelta for Janus kinase 2 activation by angiotensin II: involvement of PYK2. Mol Endocrinol 16:367-377
104. Doan TN, Ali MS, Bernstein KE 2001 Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling. J Biol Chem 276:20954-20958
105. Daviet L, Lehtonen JY, Tamura K, Griese DP, Horiuchi M, Dzau VJ 1999 Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem 274:17058-17062
106. Guo DF, Chenier I, Tardif V, Orlov SN, Inagami T 2003 Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. Biochem Biophys Res Commun 310:1254-1265
107. Shivakumar BR, Wang Z, Hammond TG, Harris RC 2004 EP24.15 interacts with the angiotensin II type I receptor and bradykinin B(2) receptor. Cell Biochem Funct 23:195-204
108. Guo DF, Tardif V, Ghelima K, Chan JS, Ingelfinger JR, Chen X, Chenier I 2004 A novel angiotensin II type 1 receptor-associated protein induces cellular hypertrophy in rat vascular smooth muscle and renal proximal tubular cells. J Biol Chem 279:21109-21120
109. Lopez-Ilasaca M, Liu X, Tamura K, Dzau VJ 2003 The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell 14:5038-5050
110. Tanaka Y, Tamura K, Koide Y, Sakai M, Tsurumi Y, Noda Y, Umemura M, Ishigami T, Uchino K, Kimura K, Horiuchi M, Umemura S 2005 The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS Lett 579:1579-1586
111. Ishizaka N, Griendling KK, Lassegue B, Alexander RW 1998 Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 32:459-466
112. Leclerc PC, Auger-Messier M, Lanctot PM, Escher E, Leduc R, Guillemette G 2002 A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling. Endocrinology 143:4702-4710
113. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW 2005 Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells. Role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 25:1824-1830
114. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, Engel A 2003 Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 278:21655-21662
115. Milligan G 2004 G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1-7
116. Jensen AA, Hansen JL, Sheikh SP, Brauner-Osborne H 2002 Probing intermolecular protein-protein interactions in the calcium-sensing receptor homodimer using bioluminescence resonance energy transfer (BRET). Eur J Biochem 269:5076-5087
117. Hansen JL, Theilade J, Haunso S, Sheikh SP 2004 Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits gαq protein signaling but not ERK activation. J Biol Chem 279:24108-24115
118. Monnot C, Bihoreau C, Conchon S, Curnow KM, Corvol P, Clauser E 1996 Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling: reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem 271:1507-1513
119. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U 2004 Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119:343-354
120. AbdAlla S, Lother H, Quitterer U 2000 AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94-98
121. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U 2001 The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276:39721-39726
122. Barki-Harrington L, Luttrell LM, Rockman HA 2003 Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108:1611-1618
123. AbdAlla S, Lother H, el Massiery A, Quitterer U 2001 Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7:1003-1009
124. Miura S, Karnik SS 2000 Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J 19:4026-4035
125. Cai H, Griendling KK, Harrison DG 2003 The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24:471-478
126. Droge W 2002 Free radicals in the physiological control of cell function. Physiol Rev 82:47-95
127. Denu JM, Tanner KG 1998 Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37:5633-5642
128. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW 1994 Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148
129. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW 2002 Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 91:1160-1167
130. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, Daniel WG 1999 Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215-222
131. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM 2002 Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105:293-296
132. El Bekay R, Alvarez M, Monteseirin J, Alba G, Chacon P, Vega A, Martin-Nieto J, Jimenez J, Pintado E, Bedoya FJ, Sobrino F 2003 Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood 102:662-671
133. Rey FE, Pagano PJ 2002 The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 22:1962-1971
134. Geiszt M, Leto TL 2004 The Nox family of NAD(P)H oxidases: host defense and beyond. J Biol Chem 279:51715-51718
135. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK 2002 Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91:406-413
136. Murasawa S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Kitabayashi I, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Iba S, Iwasaka T 2000 Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-terminal kinase. J Biol Chem 275:26856-26863
137. Huszár T, Mucsi I, Antus B, Terebessy T, Jeney C, Masszi A, Hunyady L, Mihalik B, Goldberg HJ, Thekkumkara TJ, Rosivall L 2001 Extracellular signal-regulated kinase and the small GTP-binding protein p21Rac1 are involved in the regulation of gene transcription by angiotensin II. Exp Nephrol 9:142-149
138. Touyz RM, Schiffrin EL 1999 Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 34:976-982
139. Touyz RM, Yao G, Schiffrin EL 2003 c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23:981-987
140. Lavigne MC, Malech HL, Holland SM, Leto TL 2001 Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 104:79-84
141. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG 2002 Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40:511-515
142. Barry-Lane PA, Patterson C, van der MM, Hu Z, Holland SM, Yeh ET, Runge MS 2001 p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 108:1513-1522
143. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC 2000 Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20:1529-1535
144. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK 2004 Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24:677-683
145. Endemann DH, Schiffrin EL 2004 Endothelial dysfunction. J Am Soc Nephrol 15:1983-1992
146. Schiffrin EL 2005 Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 288:H1037-H1043
147. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT 1990 Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355-1364
148. Weber KT, Brilla CG, Campbell SE 1992 Regulatory mechanisms of myocardial hypertrophy and fibrosis: results of in vivo studies. Cardiology 81:266-273
149. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
150. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
151. Ullian ME, Hutchison FN, Hazen-Martin DJ, Morinelli TA 1993 Angiotensin II-aldosterone interactions on protein synthesis in vascular smooth muscle cells. Am J Physiol 264:C1525-C1531
152. Xiao F, Puddefoot JR, Barker S, Vinson GP 2004 Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 44:340-345
153. Jaffe IZ, Mendelsohn ME 2005 Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96:643-650
154. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C 1998 Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273:4883-4891
155. Katada J, Meguro T, Saito H, Ohashi A, Anzai T, Ogawa S, Yoshikawa T 2005
156. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN 2005 Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111:3087-3094
157. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E 2002 Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143:4828-4836
158. Struthers AD, MacDonald TM 2004 Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61:663-670
159. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET 2005 Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146:973-980
160. Mihailidou AS, Funder JW 2005 Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70:347-351
161. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K 2004 Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 44:264-270
162. Imanishi T, Hano T, Nishio I 2004 Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 27:101-108
163. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M 2005 Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26:271-279
164. Sarlos S, Wilkinson-Berka JL 2005 The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci 46:1069-1077
165. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, Shinoda K, Inoue M, Shiomi T, Ikeda E, Tsubota K, Suda T, Oike Y, Ishida S 2005 Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 46:1078-1084
166. Nielsen S, Halliwill JR, Joyner MJ, Jensen MD 2004 Vascular response to angiotensin II in upper body obesity. Hypertension 44:435-441
167. Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, Labarthe D, Seidell JC, Smith Jr SC 2004 Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity. Circulation 110:e476-e483
168. Meigs JB 2003 The metabolic syndrome. Br Med J 327:61-62
169. Rajagopalan S, Harrison DG 1996 Reversing endothelial dysfunction with ACE inhibitors. A new trend. Circulation 94:240-243
170. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME 2005 Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463-473
171. Kershaw EE, Flier JS 2004 Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556
172. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K 2004 Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384-1389
173. Lin LY, Lin CY, Su TC, Liau CS 2004 Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett 574:106-110
174. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K 2004 An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576:492-497
175. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK 2004 Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687-3692
176. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K 2003 Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76-81
177. Fortuno A, Rodriguez A, Gomez-Ambrosi J, Fruhbeck G, Diez J 2003 Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 59:51-60
178. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A 2004 Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovasc Drug Rev 22:189-198
179. Zanchetti A, Ruilope LM 2002 Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 20:2099-2110
180. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR 1999 Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 107:133-139
181. Giacchetti G, Sechi LA, Rilli S, Carey RM 2005 The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16:120-126
182. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462
183. Arauz-Pacheco C, Parrott MA, Raskin P 2003 Treatment of hypertension in adults with diabetes. Diabetes Care 26(Suppl 1):S80-S82
184. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB 2004 Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 22:1779-1785
185. Doggrell SA 2003 ACE inhibitors and AT-1-receptor antagonists cooperate in non-diabetic renal disease. Expert Opin Pharmacother 4:1185-1188
186. Perez DL, De Wit C, Cohen CD, Nieto E, Molina A, Banas B, Luckow B, Vicente AB, Mampaso F, Schlondorff D 2003 Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 307:275-281
187. Ushio-Fukai M, Alexander RW 2004 Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264:85-97
188. Marsigliante S, Resta L, Muscella A, Vinson GP, Marzullo A, Storelli C 1996 AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett 110:19-27
189. Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, Ho MM, Payne JG, Vinson GP 1997 Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 75:1279-1283
190. Chen L, Re RN, Prakash O, Mondal D 1991 Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 196:280-283
191. Reddy MK, Baskaran K, Molteni A 1995 Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 210:221-226
192. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR 1998 Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 77:880-883
193. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K 2001 Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495:197-200
194. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M 2002 Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62:4176-4179
195. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M 2002 Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441-447
196. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C, Marsigliante S 2003 Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196:370-377
197. Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC 2005 Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26:459-464
198. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y 2003 Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2:1139-1147
199. Schafer B, Marg B, Gschwind A, Ullrich A 2004 Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 279:47929-47938
200. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T 2003 Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67-75
201. Fischer OM, Giordano S, Comoglio PM, Ullrich A 2004 Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 279:28970-28978
202. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW 1998 Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179-184
203. Freitas-Silva M, Pereira D, Coelho C, Bicho M, Lopes C, Medeiros R 2004 Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. Cancer Genet Cytogenet 155:42-46
204. Deshayes F, Nahmias C 2005 Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293-299
205. Smith GR, Missailidis S 2004 Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 1:3